Genmab reported positive findings from two clinical studies of epcoritamab in elderly patients with newly diagnosed diffuse large B-cell lymphoma who are not eligible for anthracycline-based chemotherapy. The update is supportive for the drug’s clinical profile and broadens its potential use in an underserved patient population. Market impact is likely limited to the individual stock given the early-stage clinical nature of the news.
Genmab reported positive findings from two clinical studies of epcoritamab in elderly patients with newly diagnosed diffuse large B-cell lymphoma who are not eligible for anthracycline-based chemotherapy. The update is supportive for the drug’s clinical profile and broadens its potential use in an underserved patient population. Market impact is likely limited to the individual stock given the early-stage clinical nature of the news.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.45
Ticker Sentiment
